Page 48 - 2018_10-Haematologica-web

V. Lapostolle et al.
References
1. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood. 1976;47(6):1031-1039.
2. Reiffers J, Faberes C, Boiron JM, et al. Peripheral blood progenitor cell transplan- tation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother. 1994;3(3):185-191.
3. D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimu- lating factor administration: adverse events. Transfus Med Rev. 2008;22(4):280-290.
4. Bari S, Seah KK, Poon Z, et al. Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation. Biol Blood Marrow Transplant. 2015;21(6):1008-1019.
5. Boiron JM, Dazey B, Cailliot C, et al. Large- scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abro- gation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion. 2006;46 (11):1934-1942.
6. Brunet de la Grange P, Vlaski M, Duchez P, et al. Long-term repopulating hematopoiet- ic stem cells and "side population" in human steady state peripheral blood. Stem Cell Res. 2013;11(1):625-633.
7. Bourdieu A, Avalon M, Lapostolle V, et al. Steady state peripheral blood provides cells with functional and metabolic characteris- tics of real hematopoietic stem cells. J Cell Physiol. 2018;233(1):338-349.
8. Leung KT, Chan KY, Ng PC, et al. The tetraspanin CD9 regulates migration, adhe- sion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. Blood. 2011;117(6):1840-1850.
9. Christopherson KW 2nd, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000-7008.
10. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repop- ulation of NOD/SCID mice on CXCR4. Science. 1999;283(5403):845-848.
11. Plett PA, Frankovitz SM, Wolber FM, Abonour R, Orschell-Traycoff CM. Treatment of circulating CD34(+) cells with SDF-1alpha or anti-CXCR4 antibody enhances migration and NOD/SCID repop- ulating potential. Exp Hematol. 2002;30(9): 1061-1069.
12. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-defi- cient NOD/SCID and NOD/SCID/B2m (null) mice. Leukemia. 2002;16(10):1992- 2003.
13. Peled A, Kollet O, Ponomaryov T, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothe- lial/stromal migration and engraftment of NOD/SCID mice. Blood. 2000;95(11):3289- 3296.
14. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1(6):635-645.
15. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long- term multilineage engraftment. Science. 2011;333(6039):218-221.
16. Bhatia M. AC133 expression in human stem cells. Leukemia. 2001;15(11):1685- 1688.
17. Bauer N, Fonseca AV, Florek M, et al. New insights into the cell biology of hematopoi- etic progenitors by studying prominin-1 (CD133). Cells Tissues Organs. 2008;188 (1-2):127-138.
18. Drake AC, Khoury M, Leskov I, et al. Human CD34+ CD133+ hematopoietic stem cells cultured with growth factors including Angptl5 efficiently engraft adult NOD-SCID Il2rgamma-/- (NSG) mice. PloS One. 2011;6(4):e18382.
19. Ivanovic Z, Duchez P, Morgan DA, et al. Whole-blood leuko-depletion filters as a source of CD34+ progenitors potentially usable in cell therapy. Transfusion. 2006;46(1):118-125.
20. Peytour Y, Guitart A, Villacreces A, et al. Obtaining of CD34+ cells from healthy blood donors: development of a rapid and efficient procedure using leukoreduction filters. Transfusion. 2010;50(10):2152-2157.
21. Duchez P, Chevaleyre J, Brunet de la Grange P, et al. Cryopreservation of hematopoietic stem and progenitor cells amplified ex vivo from cord blood CD34+ cells. Transfusion. 2013;53(9):2012-2019.
22. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guide- lines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5(3):213-226.
23. Frisch BJ, Calvi LM. Hematopoietic stem cell cultures and assays. Methods Mol Biol. 2014;1130:315-324.
24. Ivanovic Z, Duchez P, Chevaleyre J, et al. Clinical-scale cultures of cord blood CD34(+) cells to amplify committed pro- genitors and maintain stem cell activity. Cell Transplant. 2011;20(9):1453-1463.
25. Robert-Richard E, Ged C, Ortet J, et al. Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice. Haematologica. 2006;91(10):1384.
26. Chevaleyre J, Duchez P, Rodriguez L, et al. Busulfan administration flexibility increas- es the applicability of scid repopulating cell assay in NSG mouse model. PloS One. 2013;8(9):e74361.
27. Ivanovic Z, Hermitte F, Brunet de la Grange P, et al. Simultaneous maintenance of human cord blood SCID-repopulating cells and expansion of committed progenitors at low O2 concentration (3%). Stem Cells. 2004;22(5):716-724.
28. Woodard LE, Nimmagadda S. CXCR4- based imaging agents. J Nucl Med. 2011;52(11):1665-1669.
29. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone mar- row or mobilized peripheral blood as meas- ured by the quantitative in vivo SCID- repopulating cell assay. Blood. 1997;89(11):3919-3924.
30. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.
31. Denning-Kendall PA, Evely R, Singha S, Chapman M, Bradley BA, Hows JM. In vitro expansion of cord blood does not pre-
vent engraftment of severe combined immunodeficient repopulating cells. Br J Haematol. 2002;116(1):218-228.
32. Duchez P, Rodriguez L, Chevaleyre J, et al. Interleukin-6 enhances the activity of in vivo long-term reconstituting hematopoiet- ic stem cells in "hypoxic-like" expansion cultures ex vivo. Transfusion. 2015;55(11):2684-2691.
33. Jing D, Fonseca AV, Alakel N, et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells--modeling the niche compartments in vitro. Haematologica. 2010;95(4):542-550.
34. Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34+ cell mobi- lization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600-609.
35. Lataillade JJ, Clay D, Dupuy C, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor sur- vival. Blood. 2000;95(3):756-768.
36. Rosu-Myles M, Gallacher L, Murdoch B, et al. The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. Proc Natl Acad Sci USA. 2000;97(26):14626-14631.
37. Kahn J, Byk T, Jansson-Sjostrand L, et al. Overexpression of CXCR4 on human CD34+ progenitors increases their prolifer- ation, migration, and NOD/SCID repopu- lation. Blood. 2004;103(8):2942-2949.
38. Herrera C, Sanchez J, Torres A, Pascual A, Rueda A, Alvarez MA. Pattern of expres- sion of CXCR4 and adhesion molecules by human CD34+ cells from different sources: role in homing efficiency in NOD/SCID mice. Haematologica. 2004;89(9):1037- 1045.
39. Kollet O, Petit I, Kahn J, et al. Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be func- tionally expressed and provide NOD/SCID repopulation. Blood. 2002;100(8):2778- 2786.
40. Christopherson KW 2nd, Uralil SE, Porecha NK, Zabriskie RC, Kidd SM, Ramin SM. G- CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the func- tional chemotactic response of CD34+CD38- human cord blood hematopoietic cells. Exp Hematol. 2006;34 (8):1060-1068.
41. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficien- cy mice. Stem Cells Dev. 2007;16(3):347- 354.
42. Christopherson KW 2nd, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 2007;16(3): 355-360.
43. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, Mantel C. AMD3100 and CD26 modulate mobilization, engraft- ment, and survival of hematopoietic stem and progenitor cells mediated by the SDF- 1/CXCL12-CXCR4 axis. Ann N Y Acad Sci. 2007;1106:1-19.
44. Ratajczak MZ, Suszynska M. Emerging strategies to enhance homing and engraft- ment of hematopoietic stem cells. Stem Cell Rev. 2016;12(1):121-128.
1614
haematologica | 2018; 103(10)